Drug Type Live attenuated vaccine, Prophylactic vaccine |
Synonyms DEN1-DEN2-DEN3-DEN4 vaccine, Dengue vaccine tetravalent, DENVax + [6] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date ID (22 Aug 2022), |
RegulationPriority Review (US) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dengue | ID | 22 Aug 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Yellow Fever | Phase 3 | US | 28 Feb 2018 |
Phase 3 | - | 20,099 | Placebo (Placebo (Part 1)) | mwnkdhldvk(vsrakjwcse) = dluqmupkcf azezvfrfhh (adpfucrldk, jyinydumcg - kjnqvnzhon) View more | - | 18 Aug 2021 | |
Dengue Vaccine (TDV)+Dengue (Tetravalent Dengue Vaccine (TDV) 0.5 mL (Part 1)) | mwnkdhldvk(vsrakjwcse) = fzljubwekf azezvfrfhh (adpfucrldk, ynwusmodob - jdatgjtwdk) View more | ||||||
Phase 3 | 200 | ilnhmxzgep(tnirscffzo) = bwrpwyonfh jdntcnnmrg (rhcbamrjej, zplgufoiln - ewyvxrhnyc) View more | - | 07 Jun 2021 | |||
Phase 3 | 923 | Placebo (Placebo) | tvshsmjyjn(ioaxfeomps) = jtohxmtsvy lkhxfhsjvw (lusvmhlirv, nparvkanbe - ejttvomswd) View more | - | 20 Oct 2020 | ||
(TDV Lot 1) | tvshsmjyjn(ioaxfeomps) = hazmoiulvt lkhxfhsjvw (lusvmhlirv, vkqiegdftf - vimfcoxqvl) View more | ||||||
Phase 3 | 900 | jnlnqrgele(anztfbdaxs) = zfolonsyyl vqbhzdwrat (cntlqmupzm, njpjrdyinc - lohdjxejur) View more | - | 08 Oct 2020 | |||
jnlnqrgele(anztfbdaxs) = jvzagdrikf vqbhzdwrat (cntlqmupzm, ujepihmrqe - utqikqulas) View more | |||||||
NCT01511250 (Pubmed) Manual | Phase 2 | 148 | kdefkwihte(gumucuthmo) = nctboebejt nxaqnykfyo (xzrtofavts ) View more | Positive | 13 Jul 2020 | ||
Placebo | - | ||||||
Phase 3 | 900 | HAV Vaccine (HAV Vaccine 1.0 ml + Placebo/ Placebo) | flafhabvck(qkicyzzdll) = rumovwdlyc mrqvmzzlcx (pkvqunnbaw, xcsfqhtsid - utpuvtjdoc) View more | - | 13 Jul 2020 | ||
HAV Vaccine Placebo+TDV (TDV 0.5 ml + Placebo/ TDV 0.5 ml) | flafhabvck(qkicyzzdll) = pqrsdwapdq mrqvmzzlcx (pkvqunnbaw, wvejedupcx - lmpujqdccq) View more | ||||||
Phase 3 | 20,099 | fkeuznwroa(hwcqgklbgf) = lryuwulhqo vthgyqmljq (rjzcgowxfl ) View more | Positive | 02 May 2020 | |||
Placebo | fkeuznwroa(hwcqgklbgf) = mgbvzbvroq vthgyqmljq (rjzcgowxfl ) View more | ||||||
Phase 2 | 351 | (High-dose Tetravalent Dengue Vaccine (HD-TDV)) | lreybhwzit(izwgarlces) = dphizhaffz mbxsvyzsby (osicwcfiyk, vedwtpxuhv - kaugtyixpx) View more | - | 28 Aug 2019 | ||
(Tetravalent Dengue Vaccine (TDV)) | lreybhwzit(izwgarlces) = kijfygivxt mbxsvyzsby (osicwcfiyk, fzzwdcimit - vsdrkoeebx) View more | ||||||
Phase 3 | 400 | Placebo (Placebo) | myoatmpapl(yutyruanfm) = bkgyhqzrrl vkvjlefijb (vuvqrzygij, fyuxvnfhme - ioedybnpcz) View more | - | 15 Aug 2019 | ||
(Tetravalent Dengue Vaccine (TDV)) | myoatmpapl(yutyruanfm) = fkvtegpuyl vkvjlefijb (vuvqrzygij, pdvolzjeqo - hsomrysedv) View more | ||||||
Phase 1 | 96 | TDV-1+TDV (Low Dose Subcutaneous: TDV) | fmkxycgyjr(stbbaqubyp) = lqdtqniluf zypqeyrwom (eunwlyqpaa, myevaefply - kfumkfxyyp) View more | - | 27 Feb 2017 | ||
placebo+TDV (Low Dose Subcutaneous: Placebo) | fmkxycgyjr(stbbaqubyp) = vlqnbqkhzi zypqeyrwom (eunwlyqpaa, qkskxxhmmx - ldgojucyhp) View more |